Literature DB >> 30837321

Caught in the act: LRRK2 in exosomes.

Shijie Wang1, Andrew B West2.   

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a frequent genetic cause of late-onset Parkinson's disease (PD) and a target for therapeutic approaches. LRRK2 protein can influence vesicle trafficking events in the cytosol, with action both in endosomal and lysosomal pathways in different types of cells. A subset of late endosomes harbor intraluminal vesicles that can be secreted into the extracellular milieu. These extracellular vesicles, called exosomes, package LRRK2 protein for transport outside the cell into easily accessed biofluids. Both the cytoplasmic complement of LRRK2 as well as the exosome-associated fraction of protein appears regulated in part by interactions with 14-3-3 proteins. LRRK2 inside exosomes have disease-linked post-translational modifications and are relatively stable compared with unprotected proteins in the extracellular space or disrupted cytosolic compartments. Herein, we review the biology of exosome-associated LRRK2 and the potential for utility in diagnosis, prognosis, and theragnosis in PD and other LRRK2-linked diseases.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  LRRK2; Parkinson disease; biomarker; exosome; neurodegeneration

Mesh:

Substances:

Year:  2019        PMID: 30837321      PMCID: PMC6944476          DOI: 10.1042/BST20180467

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  54 in total

1.  Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Authors:  Sudad Saman; WonHee Kim; Mario Raya; Yvonne Visnick; Suhad Miro; Sarmad Saman; Bruce Jackson; Ann C McKee; Victor E Alvarez; Norman C Y Lee; Garth F Hall
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

2.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 3.  Extracellular vesicles--Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases.

Authors:  Bradley M Coleman; Andrew F Hill
Journal:  Semin Cell Dev Biol       Date:  2015-02-20       Impact factor: 7.727

4.  Localization of LRRK2 to membranous and vesicular structures in mammalian brain.

Authors:  Saskia Biskup; Darren J Moore; Fulvio Celsi; Shinji Higashi; Andrew B West; Shaida A Andrabi; Kaisa Kurkinen; Seong-Woon Yu; Joseph M Savitt; Henry J Waldvogel; Richard L M Faull; Piers C Emson; Reidun Torp; Ole P Ottersen; Ted M Dawson; Valina L Dawson
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

Review 5.  Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.

Authors:  Alberto J Espay; Michael A Schwarzschild; Caroline M Tanner; Hubert H Fernandez; David K Simon; James B Leverenz; Aristide Merola; Alice Chen-Plotkin; Patrik Brundin; Marcelo A Kauffman; Roberto Erro; Karl Kieburtz; Daniel Woo; Eric A Macklin; David G Standaert; Anthony E Lang
Journal:  Mov Disord       Date:  2017-02-24       Impact factor: 10.338

6.  CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Authors:  Ju-Hee Kang; Brit Mollenhauer; Christopher S Coffey; Jon B Toledo; Daniel Weintraub; Douglas R Galasko; David J Irwin; Vivianna Van Deerlin; Alice S Chen-Plotkin; Chelsea Caspell-Garcia; Teresa Waligórska; Peggy Taylor; Nirali Shah; Sarah Pan; Pawel Zero; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Caroline M Tanner; Tanya Simuni; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; John Q Trojanowski; Leslie M Shaw
Journal:  Acta Neuropathol       Date:  2016-03-28       Impact factor: 17.088

7.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Authors:  Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

8.  Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.

Authors:  Ying Fan; Andrew J M Howden; Adil R Sarhan; Pawel Lis; Genta Ito; Terina N Martinez; Kathrin Brockmann; Thomas Gasser; Dario R Alessi; Esther M Sammler
Journal:  Biochem J       Date:  2018-01-02       Impact factor: 3.857

9.  A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Authors:  Kevin M Biglan; David Oakes; Anthony E Lang; Robert A Hauser; Karen Hodgeman; Brittany Greco; Jillian Lowell; Rebecca Rockhill; Ira Shoulson; Charles Venuto; Diony Young; Tanya Simuni
Journal:  Ann Clin Transl Neurol       Date:  2017-05-09       Impact factor: 4.511

10.  Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.

Authors:  Anne Stuendl; Marcel Kunadt; Niels Kruse; Claudia Bartels; Wiebke Moebius; Karin M Danzer; Brit Mollenhauer; Anja Schneider
Journal:  Brain       Date:  2015-12-08       Impact factor: 13.501

View more
  5 in total

Review 1.  LRRK2 in Parkinson disease: challenges of clinical trials.

Authors:  Eduardo Tolosa; Miquel Vila; Christine Klein; Olivier Rascol
Journal:  Nat Rev Neurol       Date:  2020-01-24       Impact factor: 42.937

Review 2.  The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease.

Authors:  Alexia Polissidis; Lilian Petropoulou-Vathi; Modestos Nakos-Bimpos; Hardy J Rideout
Journal:  Biomolecules       Date:  2020-06-16

Review 3.  Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Front Neurosci       Date:  2019-12-12       Impact factor: 4.677

Review 4.  Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.

Authors:  Loredana Leggio; Greta Paternò; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Gabriele Raciti; Fabrizio Pappalardo; Carmela Giachino; Salvatore Caniglia; Maria Francesca Serapide; Bianca Marchetti; Nunzio Iraci
Journal:  Biomolecules       Date:  2020-09-16

5.  Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.

Authors:  Jillian H Kluss; Melissa Conti Mazza; Yan Li; Claudia Manzoni; Patrick A Lewis; Mark R Cookson; Adamantios Mamais
Journal:  Mol Neurodegener       Date:  2021-03-19       Impact factor: 14.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.